Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

GILEAD SCIENCES, INC.

(GILD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Gilead Sciences : RBC Boosts Price Target on Gilead Sciences to $84 From $81, Maintains Outperform Rating

07/30/2021 | 08:38am EDT


ę MT Newswires 2021
All news about GILEAD SCIENCES, INC.
04:55pGILEAD SCIENCES : Wins Canada OK on Trodelvy for Triple-Negative Breast Cancer
MT
04:36pGILEAD SCIENCES : Marks Fifth Approval for Trodelvy« in Metastatic Triple-Negative Breast ..
BU
03:08pGILEAD SCIENCES : COVID SCIENCE-Protein found on infected cells protects virus from immune..
RE
01:12pGILEAD SCIENCES : Trodelvy Product Now Recommended As Triple-Negative Breast Cancer Treatm..
MT
11:52aGILEAD SCIENCES : Statement on New NCCN Clinical Practice Guidelines in Oncology (NCCN Gui..
PU
07:19aGILEAD SCIENCES : Pfizer begins study of oral drug for prevention of COVID-19
RE
09/23GILEAD SCIENCES : Veklury (Remdesivir) Significantly Reduced Risk of Hospitalization in Hi..
AQ
09/22GILEAD SCIENCES : Veklury Lowers Hospitalization Risk in COVID-19 Patients in Phase 3 Stud..
MT
09/22BROOKLYN IMMUNOTHERAPEUTICS : Names Roger Sidhu Chief Medical Officer
MT
09/22GILEAD SCIENCES : Veklury« (Remdesivir) Significantly Reduced Risk of Hospitalization in H..
BU
More news
Analyst Recommendations on GILEAD SCIENCES, INC.
More recommendations
Financials (USD)
Sales 2021 25 003 M - -
Net income 2021 6 530 M - -
Net Debt 2021 23 112 M - -
P/E ratio 2021 14,0x
Yield 2021 4,02%
Capitalization 88 281 M 88 281 M -
EV / Sales 2021 4,46x
EV / Sales 2022 4,39x
Nbr of Employees 13 600
Free-Float 99,9%
Chart GILEAD SCIENCES, INC.
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | GILD | US3755581036 | MarketScreener
Technical analysis trends GILEAD SCIENCES, INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Last Close Price 70,41 $
Average target price 76,21 $
Spread / Average Target 8,24%
EPS Revisions
Managers and Directors
Daniel P. O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
Merdad V. Parsey Chief Medical Officer
Flavius Martin Executive Vice President-Research
Brett A. Pletcher Secretary, Chief Compliance Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
GILEAD SCIENCES, INC.22.19%89 259
BIONTECH SE309.08%80 542
REGENERON PHARMACEUTICALS32.25%66 425
WUXI APPTEC CO., LTD.35.04%59 817
VERTEX PHARMACEUTICALS-22.31%47 634
BEIGENE, LTD.46.88%35 310